前梯度蛋白2(AGR2)多克隆抗體(生物素標記)
Biotin-Linked Polyclonal Antibody to Anterior Gradient 2 (AGR2)
GOB4; HAG2; XAG2; AG2; PDIA17; HPC8; Anterior Gradient Protein 2; Protein Disulfide Isomerase Family A,Member 17; Secreted cement gland protein XAG-2 homolog
- 編號ULAC285Ra71
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 來源抗體標記
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物生物素
- 原抗體 -
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應用WB; IHC; ICC.
如果抗體需用于流式細胞術(shù)，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 376 ¥ 878 ¥ 1254 ¥ 3135 ¥ 12540
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
該抗體是針對AGR2的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別AGR2。
用法
免疫印跡：0.2-2μg/mL;1:250-2500
免疫組織化學：5-20μg/mL;1:25-100
免疫細胞化學：5-20μg/mL;1:25-100
最佳稀釋倍數(shù)最終由用戶決定。
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| URPC285Ra01 | 前梯度蛋白2(AGR2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAC285Ra01 | 前梯度蛋白2(AGR2)多克隆抗體 | IHC |
| ULAC285Ra71 | 前梯度蛋白2(AGR2)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| UMAC285Ra22 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| UMAC285Ra23 | 前梯度蛋白2(AGR2)單克隆抗體 | WB |
| UMAC285Ra26 | 前梯度蛋白2(AGR2)單克隆抗體 | WB |
| UMAC285Ra21 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| UMAC285Ra24 | 前梯度蛋白2(AGR2)單克隆抗體 | WB |
| UMAC285Ra27 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| UMAC285Ra25 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| UKSC285Ra01 | 前梯度蛋白2(AGR2)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | 自己動手制作ELISA試劑盒的主要材料 |
參考文獻
| 雜志 | 參考文獻 |
| Cancer Biomarkers | Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma [MetaPress: n7137r6271u54118] |
| Molecular & Cellular Proteomics | Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers [PubMed: PMC3205865] |
| Prostate. | Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype [Pubmed: 22911164] |
| BMC Cancer. | Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9 [Pubmed: 24007603] |
| Clinical Cancer Research | Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer [Pubmed:25239611] |
| PLoS One | AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection [PubMed: 25875093] |
| Clinical Neurology and Neurosurgery | Serum AGR2 as a useful biomarker for pituitary adenomas [S0303846717300045] |
| Oncotarget | Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2) [Pubmed:29937991] |
| Int J Oncol | Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy?induced senescence escape [34913074] |
| International Journal of Cancer | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer [Pubmed:35689436] |
留言咨詢
